IMMUNOLOGY INFUSION Referral Form

PHONE 515.225.2930 | **FAX** 515.559.2495



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above **Patient Information** First Name DOB Gender □M □F Last 4 SSN **Primary Language** Last Name Address City Home Phone Work Phone Cell Phone Email ☐ Home Phone Primary Contact Method (check one)

Cell Phone ☐ Work Phone ☐ Text □ Email ☐ Primary Caregiver ☐ DO NOT CONTACT Primary Caregiver/Alt Contact Name (If applicable) Alt Contact Email Alt Contact Phone **Prescriber Information** Title Name of Contact Sending Referral Preferred Contact Method (check one) ☐ Email ☐ Phone ☐ Fax Referral Contact Email Office Fax Office Phone Prescriber Name/Specialty Practice/Facility Name Address City State ZIP * Please include a copy of the front and back of insurance card. * Clinical Information - Please include applicable clinical chart notes. Patient New to Therapy ☐ Naïve/New Start ☐ Therapy Restart ☐ Existing Treatment **Therapy Start Date** Sample/Starter Provided? ☐ No ☐ Yes, Provide Qty: **Date Provided:** Patient Height (cm/in): Weight (kg/lbs): Date Obtained: Therapies Tried and Failed (please list medications) Other/Concomitant Medications (please list) Allergies ☐ NKDA ☐ Drug Allergies (please list) Ship to Address $\ \square$ Home ☐ Prescriber's Office ☐ Other (please list) ICD-10 Code ☐ D80.0 Congenital Hypogam ☐ D81.9 SCID (unspecified) ☐ D83.9 CVID (unspecified) ☐ Other Prescription Information - Please Escribe if required by state law. In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications DOSE/STRENGTH REFILLS ☐ Asceniv™ 10% Rate protocol: Titrate initial and maintenance infusions per □ Peripheral Infuse grams □ 3 months ☐ Bivigam® 10% □ Central grams per kg OR manufacturer's product labeling. ☐ 6 months ☐ Gammagard® liquid 10% ☐ Port OR mg per kg intravenously □ 1 year ☐ Gammagard® S/D 5% □ Subcutaneous weeks Infusion method: every ☐ Gammagard® S/D 10% □ Gravity □ Pump ☐ Gammaked™ 10% Divide total dose over days ☐ Gammaplex® 5% (where clinically appropriate, round ☐ Gammaplex® 10% to the nearest vial size) ☐ Gamunex® C 10% ☐ Hizentra 20% ☐ Octagam® 10% ☐ Panzyga® 10% ☐ Privigen® 10% ☐ Xembify □ Vascular Access Method □ Peripheral □ Central ☐ Other: □1 month □ 3 mL ☐ Normal Saline □ Before and after infusion □ 1 year □IV 3 months D5W ☐1 month □ 3 mL ☐ Heparin 10 units/mL ☐ After infusion □1 year □IV □ 5 mL ☐ 3 months ☐ Heparin 100 units/mL □РО ☐ With each □ 25 mg ☐ After infusion □ 1 vear □ 50 mg □ Diphenhydramine □IV ☐ PRN Allergic Reaction: infusion ☐ With each □ 325 ma □ 500 ma ☐ Pre-Med: □1 year □ Acetaminophen □РО infusion □ 650 mg □1gm □М ☐ Adult 1:1000, 0.3 mL (>30kg/>66lbs) ☐ PRN Anaphylaxis □ Once □1 year □ Epinephrine Peds 1:2000, 0.3 mL (15-30kg/33-66lbs) ☐ Repeating Dose: □ SQ ☐ Other: **Prescriber Signature** Date Supervising Physician Signature (where required by state law) NPI# Date **Brand Necessary (must handwrite)** DAW (Dispense as Written) Date

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific pharmacy and medical board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compiliance with state specific requirements could result in outreach to the prescriber. Confidential it, the may also considerable in the individual of entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also confidential information, which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.